Compare CADL & RYAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CADL | RYAM |
|---|---|---|
| Founded | 1999 | 1926 |
| Country | United States | United States |
| Employees | N/A | 2325 |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.8M | 661.8M |
| IPO Year | 2021 | 2014 |
| Metric | CADL | RYAM |
|---|---|---|
| Price | $8.56 | $8.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $19.00 | $14.00 |
| AVG Volume (30 Days) | ★ 2.0M | 725.5K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.62 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $125,000.00 | ★ $1,466,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.35 | $3.35 |
| 52 Week High | $9.57 | $11.85 |
| Indicator | CADL | RYAM |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 48.59 |
| Support Level | $4.80 | $8.22 |
| Resistance Level | $9.42 | $8.80 |
| Average True Range (ATR) | 0.57 | 0.34 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 37.35 | 56.58 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.